mapping agent for use in positron emission tomography (PET). This radiotracer was made by nucleophilic radiofluorination of tosyloxyethoxy-benzovesamicol, followed by reverse phase HPLC purification, in decay corrected radiochemical yield exceeding 60%.
INTRODUCTION
Vesamicol (AH 5183) interacts with the acetylcholine transporter protein on neuronal synaptic vesicles. The concmnce of [3H]vesamicol binding sites and cholinergic marker proteins in mammalian brains has led to the suggestion that this compound might serve as a neurochemical marker for cholinergic synaptic function (1-3), and created an interest in radiolabeled variants of vesamicol as imaging agents for in vivo mapping of cholinergic neurons (4-8). The ability to visualize cholinergic function could have important applications in the study of Alzheimer's disease and dysfunctions of the parasympathetic nervous system. A subclass of analogs discovered by Rogers et al., called benzovesamicols, appear to be much more potent and selective than the parent compound (9) (10) (11) (12) . Several radioiodinated and carbon-1 1 labeled benzovesamicol analogs have been developed in our laboratories which have favorable in vivo tracer properties (3, 4, 13) . These results suggest this class of compounds holds strong potential for imaging presynaptic cholinergic function in humans.
FIuorine-18 ligands have a number of properties which make them of great interest as imaging agents. They share with "C-agents the ability for high resolution PET imaging and quantification; in addition the longer 18F half life (1 10 min) allows for imaging times as late as 8 hr after injection, and permits multiple doses to be dispensed from a single synthesis batch. Furthermore, the very high specific activities (3-10 Ci/pmol) routinely attainable via "no-carrieradded" (nca) nucleophilic I8F labeling methods provides a greater margin of safety in comparison to 11C when applying toxic compounds like vesamicol as radiotracers. Several l8F-labeled vesamicol and benzovesamicol analogs have been investigated previously (7, 14) , but there continues to be a need for an analog with optimal tracer properties that is also easily synthesized for clinical investigation.
Here is described the preparation and chemical characteristics of a new fluorine-18 analog fluoroethoxybenzovesamicol (FEOBV, 1) which we feel meets these criteria. Preliminary biological evaluation of FEOBV has robust tissue uptake characteristics (15). These studies are ongoing and full characterization of this promising agent in animals is the subject of future communications.
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RESULTS AND DISCUSSION
The synthetic paths for f18F]-1, authentic 1, precursors and side products are summarized in Scheme 1. Synthesis of the enantiomeric forms of 1 utilized the pure (-) or (+) isomers of 3 as starting materials, which had been resolved by the route shown in Scheme 2. FET to obtain an acceptable labeling yield of 1. This route was wasteful of 4, a precious chiral precursor prepared in a multistep sequence involving diazotization of resolved 3 (Schemes 1 and 2.). Another problem was that large amounts of non-radioactive side products were formed that complicated purification of [18F]-1.
The side products were characterized in an effort to improve yields, and serendipitously, one of these was found to be tosyloxyethyoxybenzovesamicol2. This combination of properties makes 2 an ideal precursor for a reliable "one-step'' synthesis of [I8F]-1. Each synthesis requires only a small quantity of 2 (0.7-1.5 mg, -1.5-3 Fmol). Chromatographic purification of [I8F]-1 is straightforward due to the lower mobility of 2, and the incorporation of a small C-18 extraction column and aqueous rinse cycle into the injection loop of the preparative HPLC simplifies sample loading and removes water soluble materials and kryptofix prior to HPLC injection. The average yield for the most recent 8 runs is 61+12%, with the end-of-synthesis radioactive amounts in the range of 9-76 mCi.
Analysis of reaction by-products indicates that oxygen nucleophiles present in the medium compete with fluoride ion for displacement of the tosylate function of 2 under standard labeling conditions. This observation has seldom been made explicitly in reported examples of N-ethyl tosylate radiofluorination although it undoubtedly occurs to a significant extent in those cases as well. Indeed, the primary (unlabeled) product in the one step labeling reaction is hydroxyethyl compound 5, which presumably results from attack of the tosylate by traces of OH-or C03-2 made soluble by the kryptofix. Deliberate hydrolysis of 2 in 3: 1: 1 CH3CNMeOH:H20 containing 0.2N NaOH quickly produces 5, and surprisingly, a nearly equivalent amount of methoxyethyl6 due to attack by methanol. These side products are of concern because of the toxicity of this general class of compounds (9). Formation of 5 during the labeling reaction can be lessened, though not avoided completely, by reducing the quantity of K2C03 to the absolute minimum--4 pmol in our experience. Fortunately 5 is substantially more polar than [18F]-1, and it is efficiently removed during HPLC purification.
In conclusion, a simple and efficient synthesis of the promising new cholinergic imaging agent FEOBV in high purity has been developed. This method uses a stable, c h i d precursor and conventional solution phase nucleophilic labeling techniques, and is amenable to large scale production (>50 mCi) of this agent using commercially available "black box" automated synthesis units with minor modifications. 
EXPERIMENTAL
1H NMR spectra were obtained in cDC13 on a Bruker 360-MHz NMR spectrometer and are reported in parts per million downfield from tetramethylsilane. l3C NMR spectra were measured at 90.56 MHz. Mass spectra were obtained in the electron impact (EI) ionization mode at 70 eV. Molecular masses are given in atomic mass units, followed by percent intensity relative to the most abundant ion. Accurate mass spectral determinations were also obtained in the EI mode at 70 eV. Elemental analyses were carried out by Spang Microanalytical Laboratory, Eagle Harbor, MI. Melting points were determined on a MEL-TEMP apparatus, and are uncorrected. (16), and was either used directly or purifEd prior to use by a silylation procedure described previously (17).
Resolution of (f)-5-aminobenzovesamicol, (3).
Enantiomers of 3 were resolved by flash chromatography of the diastereomeric bis-N,O-(S)-(-)-a-methoxy-a-trifluoromethylphenylacetyl (MTPA) derivatives (1 8). followed by reductive cleavage of the MTPA groups. To a solution of (f)-3 (9) (1.94g, 6.02 mmol), 4-dimethylaminopyridine (441 mg, 3.61 mmol), triethylamine (3.36 mL, 24.1 mmol) in dry CHC13 (15 mL) was added dropwise via syringe (S)-(-)-MTPA chloride (3.49g, 13.84 mmol) at room temperature. The resulting solution was stirred for 6 hours and then poured into ethyl acetate (30 mL). The solution was washed with saturated NaHC03 solution (30 mL) and the aqueous layers were extracted with ethyl acetate (2 x 30 mL). The combined extracts were dried over anhydrous Na2S04 and concentrated under reduced pressure. The two diastereomeric N,O-bis-MTPA isomers were separated by flash column chromatography on silica using EtOAc: CH2C12: hexane 1:2:7. The less polar compound (Rfa.25, EtOAc: CH2C12: hexane 1:2:7, silica gel) was (+)-(S,S)-bis-MTPA-diastereoisomer. It was isolated in 99% yield (2.25g). The more polar compound (Rf=0.14, 1:2:7 EtOAc: CH2C12 :hexane, silica gel), was the (-)-(R,R)-diastereoisomer. It was obtained in a yield of 2.238 (98%).
The (-)-(R,R)-bis-MTPA-diastereoisomer (2.20g, 2.92 mmol) was dissolved in dry toluene (30 mL) and cooled to -78OC. Diisobutyl aluminum hydride (1 1.7 mL of 1.0 M solution in cyclohexane, 11.7 mmol) was added dropwise via syringe. The resulting solution was stirred at -78oC for 30 min. and allowed to warm to room temperature. The reaction was quenched with 2.5 N HCl (30 mL). The aqueous layers were separated, made alkaline (pH=lO) with 3.0 N NaOH solution and extracted with CH2C12 (3 x 50 mL). The organic extracts were dried over anhydrous Na2S04 and concentrated under reduced pressure. The residue was flash-chromatographed on silica gel with 50% EtOAc in hexane to afford 880 mg (94%) of (-)-(R,R)-3 ( [ a ]~2 3 = -58.1,
C=1.5, EtOH). (+)-(R,R)-3 was obtained in 90% yield from the (+)-bis)-MTPA diastereomer using the same procedure as above ( [ a ]~2 3 = +54.7, C=1.5, EtOH). Enatiomeric purities of (-)-
and (+)-enantiomers were 9 9 % as determined by chiral HPLC using a Chiracel OD column (4.6 x 250 mm) with a 2-propanoVhexaneE~NH (5050: 1) mobile phase at a flow rate of 1 mUmin and UV detection at 254 mm. Retention times of (+)-and (-)-3 enantiomers were 8.25 and 9.44 min, respectively.
(-)-(2R,3R)-Trans--2-hydroxy-3-(4-phenylpiperidino)-5-hydroxytetralin, (-)-5-hydroxybenzovesamicol, (-)HOBV, (4).
Diazotization of (-)-3. To a solution of concentrated sulfuric acid (2 mL) and water (4 mL) was added a solution of (-)-3 (150 mg, 465 p o l ) in THF (3 mL). The resulting solution was cooled to 5oC and a solution of sodium nitrite (38.5 mg, 558 vmol) in water was added dropwise while the temperature of the solution was maintained below 7oC. The diazonium solution was stirred for 1 hour and added dropwise to a second solution of H2SO4 (2 mL) and water (10 mL) which was heated to boiling. The mixture was boiled for 5 min after the additions were completed and then allowed to cool to room temperature. The solution was brought to pH 9 with 10 N NaOH solution and extracted with ethyl acetate (3x40 mL). The combined extracts were dried over anhydrous N a 2 S 0 4 and concentrated under reduced pressure. 19.97, 33.92, 34.40, 37.93, 42.95, 45.00, 53.58, 65.49, 66.56, 112.15, 121.52, 121.93, 126.23, 126.82, 126.89, 128.46, 135.85, 146.09, 153.72 (-)-(2R,3R)-trans--2-hydroxy-3-(4-phenylpiperidino)-5-(2-tosyloxethoxy)-tetralin, (-)-5-(2-tosyloxyethoxy)-benzovesamicol, (-)TEOBV, (2) .
A solution of (-)-HOBV 4 (5 mg, 15.5 pnol) and TBAOH (17 pnol, 17 WL of a 1 M solution in MeOH) in 2 mL of acetonitrile was evaporated to dryness on a rotary evaporator at room temperature, and then dry acetonitrile (1mL ) was added to the residue and the mixture was re-evaporated to remove traces of moisture. Ethylene glycol ditosylate (74 mg, 200pmol) and 2 mL of acetonitrile were added to the residue and and the reaction mixture was warmed at 60-70' for 2 hr, or untildl HOBV had disappeared, as measured by analytical reverse phase HPLC (column: 5 micron silica C-18, mobile phase: 1.5 mumin, 3: 1: 1 CH3CN MeOH: 20 mM KHPO4, pH 6.7; ~H O B V 1.6, ~' F E O B V 3.25, k'TEOBV 6.4). The product 2 was isolated by flash chromatography on silica using a hexane: Et2O step gradient to give, after crystallization from iPrOH, 5.6 mg (69%) of white crystals of (-)TEOBV 2, mp 164-166OC. The (+) isomer was prepared in identical fashion from (+)HOBV. 
(-)-(2R,3R)-Trans--2-hydroxy-3-(4-phenylpiperidino)-5-(2-fluoroethoxy)-tetralin, (-)-5-(2-fluoroethoxy)-benzovesamicol, FEOBV, (1).
A solution of (-)-HOBV 4 (60 mg, 186 pmol) was dissolved in 3 mL of CH2C12 under inert atmosphere and 200 pL of 1 M TBAOH in MeOH was added. The solvent was removed by rotary evaporation at room temperature. To the residue was added 2mL of dry CH3CN which was then evaporated to azeotropically remove traces of moisture. This step was repeated once, The residue containing the dark phenoxide salt was resuspended in a fresh 3.5 mL portion of CH3CN and 2-fluoroethyl tosylate (50 mg, 230 pnol) was added. The mixture was heated (inert amnosphere) at 70-80' for 2 hr, or until the the consumption of HOBV was complete, as measured by HPLC. Following evaporation of reaction solvent, the crude product was partitoned between CH2C12 and water, and the CH2C12 layer was washed with 0.5N NaOH, dried (Na2S04), and concentrated to an oil, which was purified by flash chromatography (hexane:EtOAc). 
